

FOR RELEASE, April 15th, 2008



Trinity's Executive Chairman Purchases Shares in the Company

DUBLIN, Ireland April 15th 2008...- Trinity Biotech plc (Nasdaq: [TRIB](#)), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that Executive Chairman, Ronan O'Caomh, purchased 250,000 ADRs in the Company in the open market. This follows a purchase of 100,000 ADRs in the Company made by Ronan O'Caomh on March 20th, 2008.

Ronan O'Caomh, Executive Chairman of Trinity Biotech, commented, "This purchase of 250,000 ADRs, in addition to my recent purchase of 100,000 ADRs, reflects the confidence that I have in the future growth prospects and strategic direction of the Company."

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact : Trinity Biotech plc
Kevin Tansley - CFO
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com

END OF RELEASE

